ArticleScientific reports2020
Histological transformation in recurrent WHO grade I meningiomas.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Novel Nomogram for Predicting Meningioma Grade Based on Radiomics Features and Clinical Characteristics.Current medical science · 2026Article
- Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas.Acta neuropathologica communications · 2025Article
- In Silico Identification of circPIM1/miR-16-5p/miR-195-5p/PIM1 Feed-Forward Loop in Recurrent Grade 2 Meningioma.International journal of molecular sciences · 2025Article
- Article
- The role of adjuvant radiotherapy for intracranial malignant meningiomas: analysis of a nationwide database.Journal of neuro-oncology · 2024Article
- Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution.Nature genetics · 2024Article
- Postoperative [European journal of nuclear medicine and molecular imaging · 2023Article
- Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution.Research square · 2023Article
- De Novo Skull Base Atypical Meningioma: Incidence and Outcome.Journal of neurological surgery. Part B, Skull base · 2023Article
- Surgical strategies for intracranial meningioma in the molecular era.Journal of neuro-oncology · 2023Review
- Long-term outcomes of fractionated proton beam therapy for benign or radiographic intracranial meningioma.Journal of neuro-oncology · 2023Article
- Consensus core clinical data elements for meningiomas (v2021.1).Neuro-oncology · 2022Article
- Why we need new classification models in meningioma management.Acta neurochirurgica · 2022Article
- Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives.Frontiers in oncology · 2022Review
- The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.Journal of neuro-oncology · 2022Review
- Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas.International journal of molecular sciences · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical or malignant transformation (AT/MT) has been described in WHO grade I meningiomas. Our aim was to identify predictive factors of AT/MT at recurrence. A total of N = 15 WHO grade increases were observed in N = 13 patients (0.96% of the study population, risk of transformation of 0.12% per patient-year follow-up). Patients with and without progression at recurrence were similar regarding age, gender distribution, skull-base location, bone infiltration, and Simpson grades. Recurrence-free survival was lower in patients with transformation (5 ± 4.06 years versus 7.3 ± 5.4 years; p = 0.03). Among patient age, gender, skull base location, extent of resection or post-operative RT, no predictor of AT/MT was identified, despite a follow-up of 10,524 patient-years. The annual risk of transformation of WHO grade I meningiomas was 0.12% per patient-year follow-up. Despite the important number of patients included and their extended follow-up, we did not identify any risk factor for transformation. A total of 1,352 patients with surgically managed WHO grade I meningioma from a mixed retro-and prospective database with mean follow-up of 9.2 years ± 5.7 years (0.3-20.9 years) were reviewed. Recurring tumors at the site of initial surgery were considered as recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.